DON LYNN GIBBONS to Pyrimidines
This is a "connection" page, showing publications DON LYNN GIBBONS has written about Pyrimidines.
Connection Strength
0.325
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
Score: 0.097
-
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Sci Transl Med. 2019 03 13; 11(483).
Score: 0.070
-
Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy. Proc Natl Acad Sci U S A. 2014 Mar 04; 111(9):3550-5.
Score: 0.050
-
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments. Mol Oncol. 2013 Oct; 7(5):968-75.
Score: 0.047
-
The rise and fall of gatekeeper mutations? The BCR-ABL1 T315I paradigm. Cancer. 2012 Jan 15; 118(2):293-9.
Score: 0.041
-
A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.
Score: 0.019